3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
8
Liver Neoplasms
5
Carcinoma, Hepatocellular
4
Lung Neoplasms
3
Squamous Intraepithelial Lesions
2
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Pancreatic Cancer
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasm Metastasis
1
Melanoma
1
Lymphatic Metastasis
1
Liver, Cancer of, Non-Resectable
1
Laryngeal Neoplasms
1
Hilus Pulmonary Neoplasms
1
Head and Neck Neoplasms
1
HIV Seropositivity
1
Gallbladder Neoplasms
1
Extremities Neoplasms
1
Esophageal Neoplasms
1
Colorectal Liver Metastases
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
9
Cisplatin
5
vinflunine
4
Carboplatin
4
pembrolizumab
2
enfortumab vedotin
2
Ramucirumab
2
Platinum
2
Docetaxel
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
genexol-PM
1
eribulin
1
enzalutamide
1
dehydroftorafur
1
carotuximab
1
avelumab
1
atezolizumab
1
abexinostat
1
Vitamin D
1
Specimen Handling
1
Sorafenib
1
Radiotherapy
1
Radiation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide
1
Molecular Diagnostic Techniques
1
Mitozytrex
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Ureteral Neoplasms
×
Electroporation
×
Clear all
NCT02430779
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
30 enrolled